Showing 691-700 of 7756 results for "".
Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/series/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.Hair Today
https://practicaldermatology.com/conferences/scale-2023/hair-today/20204/Joel L. Cohen, MD, and Doris Day, MD, discuss the latest advances in treating hair loss including the use of lasers with topicals, supplements, or PRP injections. They also discuss some of the risks associated with the use of biotin as a hair growth supplement.DermWireTV: USPSTF Tackles Racism; Winlevi Launch; Derm Days in Focus
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-uspstf-tackles-racism-winlevi-launch-derm-days-in-focus/20014/The US Preventive Services Task Force is undertaking efforts to mitigate the influence of systemic racism in its recommendations. Global Psoriasis Day, National Biologics Coordinators Day, and Retinol Day bring attention to skin issues. Sun Pharmaceutical’s Winlevi (clascoterone) cream 1% is now avaNew Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a highScientifically Speaking: Diagnosing and Treating Hair Loss, Part 1
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-diagnosing-and-treating-hair-loss-part-1/19954/Hair loss is distressing for many patients. The first step in management is to identify the cause of hair loss, modify contributing factors, and develop an effective treatment plan. Host Joel L. Cohen, MD discusses the challenges of managing hair loss with Marc Avram, MD, Cheryl Burgess, MD, and ReeDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiWhy social networking for your practice is more important than ever
https://practicaldermatology.com/topics/practice-management/why-social-networking-for-your-practice-is-more-important-than-ever/19811/In uncertain times, acquiring and retaining patients can be more difficult than ever. This Ekwa Marketing video discusses how social media can help you connect, communicate, and boost your professional reputation.COVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditi